|Bid||18.71 x 40700|
|Ask||18.71 x 28000|
|Day's range||18.36 - 18.72|
|52-week range||8.82 - 21.86|
|Beta (5Y monthly)||1.22|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.
The continued momentum is a result of CymaBay's announcement yesterday of positive top-line results from a late-stage clinical study evaluating experimental drug seladelpar in treating primary biliary cholangitis (PBC), a rare chronic inflammatory liver disease. The great news for CymaBay, though, is that seladelpar appears to have a key advantage over those other PBC treatments. The results from the company's phase 3 study found that it significantly reduced itching, which is a major issue for many PBC patients.
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.